Company news

Viridian Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

October 20, 2026

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

August 6, 2026

Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)

July 16, 2026

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa(TM) (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

June 26, 2026

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

June 26, 2026

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

May 6, 2026

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

May 5, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

May 5, 2026

Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

March 31, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL?1 Clinical Trial in Active Thyroid Eye Disease

March 30, 2026

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

March 29, 2026

Bambusa Therapeutics Appoints Todd James Chief Financial Officer

March 19, 2026

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

February 26, 2026

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 8, 2026

Viridian Therapeutics Prepares for Transformational 2026

January 6, 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

December 21, 2025

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 4, 2025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

November 2, 2025

Viridian Therapeutics Announces Proposed Underwritten Public Offering

October 20, 2025

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

October 20, 2025

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

October 19, 2025

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

September 14, 2025

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

August 5, 2025

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

July 29, 2025

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 29, 2025

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 19, 2025

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 6, 2025

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 5, 2025

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

April 6, 2025

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

February 26, 2025

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

January 7, 2025

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

December 15, 2024

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

December 12, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

November 11, 2024

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

September 10, 2024

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

September 9, 2024

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

September 9, 2024

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

September 8, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

August 7, 2024

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

July 24, 2024

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

June 10, 2024

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 30, 2024

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 9, 2024

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 7, 2024

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

April 28, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 4, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

February 26, 2024

Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.